Peptide Evidence Labels: Preclinical to Phase III

When a peptide is described as “clinically studied” or “backed by research,” the useful question is not whether research exists but what kind. A dish of cells, a handful of mice, a 30-person safety study, and a 3,000-patient confirmatory trial are all “research,” yet they carry wildly different weight. Understanding the evidence ladder, preclinical through Phase III, is what lets you read a peptide claim without being fooled by the word “study.” Our peptide research glossary collects these terms in one place; this article walks the ladder rung by rung so the labels mean something to you.

The ladder, top to bottom

Drug development is a filter, not a formality. Each stage asks a narrower, higher-stakes question, and most candidates drop out along the way. The U.S. Food and Drug Administration describes the process in five stages: discovery and preclinical research, then three clinical phases in humans, FDA review, and finally post-market safety monitoring.

Stage	Tested in	Core question	Typical size
Preclinical	Cells (in vitro), then animals (in vivo)	Is it plausibly safe and active enough to try in people?	Lab and animal models
Phase I	Healthy volunteers (or patients, in oncology)	Is it safe? What dose range is tolerated?	20–100 people
Phase II	Patients with the target condition	Does it show any real effect? What are the side effects?	Up to several hundred
Phase III	Larger patient population	Does the benefit hold up against a control, at scale?	300–3,000 people
Phase IV	General population after approval	What shows up in long-term, real-world use?	Several thousand

Each rung tests a different question, and roughly nine of ten drugs that enter human trials never reach approval, so ‘it works’ at one rung says little about the next.

Those participant counts are the FDA’s own, from its description of Step 3 of the drug development process.

The numbers matter less than the logic: you move down the ladder only by surviving the question above.

Preclinical: the rung almost everything starts on

Preclinical work happens before any human ever takes the compound. It combines in vitro experiments (cells or tissue in a dish) and in vivo experiments (living animals, usually rodents) to gather early signals on activity, toxicity, and how the body handles the molecule. Its job is narrow: decide whether a candidate is promising and safe enough to justify testing in people at all.

This is the rung that matters most for anyone reading peptide marketing, because this is where the overwhelming majority of research peptides live. A compound with striking results in rat tendon healing or mouse tissue repair has cleared the first filter, and only that one. It has not been shown to be safe or effective in humans, because those questions have not yet been asked. The gap between a strong animal result and a human benefit is wide and frequently fatal to a drug candidate, a translation problem we cover in animal data versus human data: the peptide translation gap.

Phase I: is it safe in people?

Phase I is the first time humans are dosed. It enrolls a small group, on the order of 20 to 80 volunteers, who are closely monitored to find a tolerated dose range, characterize how the drug is absorbed and cleared, and catch obvious safety problems. Efficacy is not the main point here; the trial is usually too small and too short to prove a compound works. Passing Phase I means “we didn’t see a red flag at these doses,” nothing more.

Phase II: does it do anything?

Phase II is the first real efficacy test, in patients who have the condition the drug is meant to treat. These studies are still relatively small (roughly a few hundred people) and are designed to generate preliminary evidence of benefit and a clearer side-effect profile. Phase II is famously where hopeful candidates go to die. Many compounds that looked good in a dish and were tolerated in Phase I fail to move the disease. A drug that has “completed Phase II” has cleared a meaningful bar; one only “in Phase II” has not.

Phase III: the confirmatory test

Phase III is the large, rigorous trial most people picture when they hear “clinical trial”: randomized, controlled (often against placebo or standard care), sometimes run across many sites, and large enough, hundreds to thousands of patients, to confirm a benefit and detect less common risks. This is the evidence regulators lean on most heavily for approval. It is expensive, slow (often years), and decisive.

The attrition is the point

Here is the number that reframes every “studied” claim: of the drug candidates that enter human trials, only a small minority is ever approved. The largest published analysis — Wong, Siah and Lo’s study of 406,038 trial records covering 21,143 compounds between 2000 and 2015 — puts the overall probability of getting from Phase 1 to approval at 13.8%. Earlier estimates using smaller industry databases came out lower: 10.4% and 9.6%. So somewhere between roughly one in seven and one in ten makes it, depending on whose dataset you use.

The attrition is spread across every rung. The FDA’s own figures: approximately 70% of drugs move past Phase 1, approximately 33% move past Phase 2, and approximately 25-30% move past Phase 3. Wong and colleagues, counting differently, get 66.4% past Phase 1, 58.3% past Phase 2, and 59.0% past Phase 3. The two sets disagree — which is itself worth knowing — but they agree on the shape: Phase 2 is the steepest drop, and no rung is a formality. Treat any single percentage as an order of magnitude, not a constant.

The lesson for peptides is direct. “Show me a study” is the wrong filter, because a study can be a mouse experiment or a 3,000-person trial. The right filter is: which rung, and did it pass, or is it still in progress? A peptide with only preclinical data has crossed a threshold that roughly every eventual failure also crossed. That is not nothing, but it is nowhere near proof.

Where research peptides sit

Most of the peptides sold as “research chemicals” (the tendon-and-tissue repair compounds, the growth-hormone secretagogues, the copper peptides) have preclinical data and, in some cases, small early human studies for a specific medical use that is different from how they’re marketed. Very few have completed Phase III trials for the outcomes people buy them for, and most are not approved for human use at all. When a peptide does have a defined regulatory status or trial history, that context changes how you should read every claim about it, the reason it’s worth knowing what phase a peptide is in and why it matters before drawing any conclusions.

The honest bottom line

The evidence ladder exists because good-looking early results usually don’t survive contact with rigorous human testing. Preclinical means “promising in cells or animals.” Phase I means “tolerated in a few people.” Phase II means “shows early signs of working.” Phase III means “confirmed at scale.” Approval means it cleared all of it. Most research peptides are on the bottom rung, and honest reading starts by naming which rung you’re looking at. Keep the peptide research phases and terminology reference handy, treat “studied” as a question rather than an answer, and remember that none of this is medical advice. Research peptides are mostly not approved for human use, and this is educational context only. Consult a qualified clinician before acting on anything health-related.

Sources

• U.S. FDA — The Drug Development Process (five stages; Phase 1 typically 20–80 subjects; clinical research overview). fda.gov (page not deep-linked here because it was not independently confirmed to resolve from our tooling).